Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …

ABSTRACT The US Food and Drug Administration (FDA)'s recent accelerated approval of
two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …

Over the past 30 years, the majority of (pre) clinical efforts to find an effective therapy for
Alzheimer's disease (AD) focused on clearing the β-amyloid peptide (Aβ) from the brain …

Purinergic receptors (Rs) of the ATP/ADP, UTP/UDP (P2X, P2Y) and adenosine (A1, A2A)-
sensitive classes broadly interfere with cognitive processes both under quasi normal and …

Cognitive decline is one of the most important consequences of aging and pharmacological
therapies had been largely unsuccessful. Other strategies include the use of functional foods …

Dementia is a leading global public health challenge. Prevention approaches have
traditionally focused on individual‐level strategies. However, such approaches have limited …

Decades of research have demonstrated an incontrovertible role of amyloid-β (Aβ) in the
etiology of Alzheimer's disease (AD). However, the overemphasis on the pathological …

Background Interventional trials that evaluate treatment effects using surrogate endpoints
have become increasingly common. This paper describes four linked empirical studies and …

The need for regulatory approval of new therapies for the treatment of Alzheimer's disease—
a progressive neurodegenerative condition—has made the assessment of treatment efficacy …